Health Tech Firm Combinostics Raises €3.9 Million for Expansion to USA and Asia

  • Combinostics secured €3.9 million in Series A funding.
  • The funds will be used to scale to Asia and USA.
  • Combinostics enables early diagnosis of neurological disorders.

This week, Combinostics has closed its Series A funding round. As a result, expansion and research and development are in the future for Combinostics. 

Health Tech Firm Combinostics Secures €3.9 Million in Funding

Combinostics, a leading Finnish health tech company, has raised €3.9 million in Series A funding this week. Overall, the funds were contributed largely by Industrifonden and NordicNinja VC and will help Combinostics further its cause in the US and Asia. 

Combinostics CEO Lennart Thurfjell said on the occasion, ‘I would like to thank Industrifonden and NordicNinja for demonstrating their trust in Combinostics with this investment, as well as our previous early-stage angel investors.’

Combinostics to Scale its Platform to US and Asia

Moving forward, Combinostics will use the funding to launch its operations in the U.S. and Asian countries like China and Japan. ‘We will use this investment to ramp up R&D, build our US operations, and expand in Asia. We currently have a partner working on regulatory approval in Japan, and we are looking for a partner in China,’ said Thurfjell. 

In a bid to improve treatment, the company has developed a platform that enables physicians to diagnose neurological disorders earlier.

Combinostics Helps in Early Diagnosis of Neurological Disorders

Neurological disorders like Alzheimer’s don’t have any proper treatment. Early diagnosis and subsequent lifestyle changes and symptomatic treatment can increase the quality of a patient’s life. 

‘Imaging data gets larger and larger in volume, and there is new information all the time. We help to turn this data into insights.’

In the diagnostic process, physicians have to analyse a huge amount of data that makes interpretation and decision-making difficult. For instance, Combinostic’s platform performs brain scans and compares them with clinical data to develop the patient’s profile. Subsequently, Physicians can compare the profile with previous diagnostic data to develop a better understanding of the disease and its stage.

‘If a physician suspects the patient has a certain disease and then sees the relevant data points in this direction, they will feel more confident to do the diagnosis at an early stage,’ said Thurfjell.

Who’s Behind the Idea

A team of professionals work for Combinostics with an aim to facilitate early diagnosis for better treatment. That is to say, the platform turns data into insights to help physicians in decision-making.

Thomas Brömme
Thomas Brömme
Thomas ist Gründer und Head of StartupTV. Er ist verantwortlich für Konzeption, Strategie und Finanzen.

More from author

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!